A multidisciplinary centre launched today will promote a far broader understanding of the role sugars play in human disease, scientists say.
Focused on glycobiology, the study of how sugars in human cells affect our biology, researchers hope it will accelerate the development of therapies for diseases such as HIV, cancers and muscular dystrophy.
The Glycobiology Training, Research and Infrastructure Centre (GlycoTRIC), established at Imperial College London, will promote research at the interface between biochemistry and medicine with the aim of pushing forward both knowledge in this area and its application. This in turn will foster an ideal environment for training the next generation of researchers, according to the head of the Centre, Professor Anne Dell, who explains:
"Glycobiology is an extremely broad subject, since the way sugars work can only be fully understood within the context of the whole body. This is the first centre in the UK to bring together experts in areas such as biochemistry, genetics and physiology and promises to revolutionise our understanding of human disease."
The study of glycobiology is based on understanding the specific biological functions of the complex mixtures of sugars found in cells. The key focus of GlycoTRIC will be to increase our understanding of what these functions are and how they are performed, leading ultimately to concrete applications in medicine and biotechnology.